| Drug Name |
Atogepant |
| Drug ID |
BADD_D02529 |
| Description |
Atogepant is an oral antagonist of calcitonin gene-related peptide (CGRP) receptors indicated for the prevention of episodic migraine headaches. It was developed by AbbVie and received FDA approval under the brand name Qulipta in September 2021.[L38814] While its approval was predated by two other members of the same drug family, namely [ubrogepant] and [rimegepant], these agents are indicated only for abortive migraine therapy - atogepant is novel in that it is the first and only oral CGRP antagonist approved for preventative use in migraine.[L38814]
In patients requiring preventative migraine therapy, current practice guidelines recommend the use of certain anti-epileptic medications (e.g. [valproic acid] or [topiramate]) or beta-blockers (e.g. [propranolol]), all of which can be associated with significant adverse effects.[A239094] The "gepants" family of drugs, including atogepant, are comparatively well-tolerated[A189207,L38739] and may provide a desirable treatment option for patients struggling with adverse reactions to other preventative therapies. |
| Indications and Usage |
Atogepant is indicated for the prevention of episodic migraine in adults.[L38739] |
| Marketing Status |
approved; investigational |
| ATC Code |
N02CD07 |
| DrugBank ID |
DB16098
|
| KEGG ID |
D11313
|
| MeSH ID |
C000718987
|
| PubChem ID |
72163100
|
| TTD Drug ID |
D02ZUG
|
| NDC Product Code |
0074-7093; 0074-7092; 0074-7091; 0074-7096; 0074-7094; 0074-7095 |
| UNII |
7CRV8RR151
|
| Synonyms |
atogepant | (3S)-N-((3S,5S,6R)-6-methyl-2-oxo-1-(2,2,2-trifluoroethyl)-5-(2,3,6-trifluorophenyl)piperidin-3-yl)-2-oxospiro(1H-pyrrolo(2,3-b)pyridine-3,6'-5,7-dihydrocyclopenta(b)pyridine)-3'-carboxamide |
